Sequencing Reagents Market Analysis

Technology (Next Generation Sequencing, Sanger Sequencing, Third Generation Sequencing)

The next-generation sequencing segment in the will grow the most by the forecast period and will hold almost 45% in the sequencing reagents market because of its high possibility for the growth of companion diagnostics and customized medicine for the treatment of chronic diseases. Next-generation sequencing (NGS) may empower more centered and profoundly personalized cancer treatment, with the National Comprehensive Cancer Arrange and European Society for Restorative Oncology rules presently prescribing NGS for everyday clinical hone for a few tumor sorts. Be that as it may, NGS usage, and thus persistent get to, changes over Europe; a multi-stakeholder collaboration is required to set up the conditions required to progress this disparity. In that respect, the analysts set up European Collusion for Customized Pharmaceutical (EAPM)-led master boards amid the primary half of 2021, counting key partners from over 10 European countries covering restorative, financial, quiet, industry, and legislative mastery. NGS tests are ordinarily run to realize a foreordained scope, which is the normal profundity of sequencing overall focused on genome positions. Scope at any genome arrangement can be calculated, after mapping sequencing peruses to the reference genome, by tallying the number of autonomous peruses that cover that position and thus will propel the sequencing reagents market.

Application (Clinical Investigation, Oncology, Forensics & Agrigenomics, Virology, RNA Sequencing, Metagenomics)

The oncology segment is expected to hold around 38% share of the global sequencing reagents market by 2037, owing to the increasing implementation of next-generation sequencing for cancer diagnosis and treatment across the world. Next-generation sequencing testing selection rates have expanded in later a long time, with rates for progressed non–small cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC), and progressed melanoma expanding from less than 1% in 2011 to approximately 40% in 2022. Thus, it will help this segment to have the largest growth in the sequencing reagents market.

Our in-depth analysis of the global sequencing reagents market includes the following segments:

Type	Template Kits Library Kits Control Kits Sequencing Kits
Technology	Next Generation Sequencing Sanger Sequencing Third Generation Sequencing
Application	Clinical Investigation Oncology Forensics & Agrigenomics Virology RNA Sequencing Metagenomics
Reagent Type	DNTP Reagent DNA Polymerase Reagent Ampicillin Reagent Buffer Solution Reagent NGS Reagent Serum Reagent Kits
End-Use Industry	Academic Research Clinical Research Hospitals & Clinics Pharmaceutical & Biotechnology Companies

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of sequencing reagents is assessed at USD 9 billion.

Sequencing Reagents Market size was valued at USD 7.93 billion in 2024 and is likely to reach USD 59.71 billion by the end of 2037, expanding at around 16.8% CAGR during the forecast period i.e., between 2025-2037. The quick development in sequencing technology will drive the market growth.

North America industry is set to dominate majority revenue share of 34% by 2037, owing to regions advanced healthcare system.

The major players in the market are Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN, BGI, Pacific Biosciences of California, Inc., F. Hoffmann-La Roche A.G., Oxford Nanopore Technologies, Agilent Technologies, Inc., Fluidigm Corporation, ArcherDX, Inc., Myriad Genetics. Inc., Eurofins Scientific, Takara Bio Inc., Mitsui Information Co., Ltd.

Sequencing Reagents Market Analysis